Your browser doesn't support javascript.
loading
Gender differences in treatment of Coronavirus Disease-2019.
Ambrosino, Immacolata; Barbagelata, Elena; Corbi, Graziamaria; Ciarambino, Tiziana; Politi, Cecilia; Moretti, Anna Maria.
Afiliação
  • Ambrosino I; Local Healthcare Unit of Bari, Health District 10. imma-ambrosino@libero.it.
  • Barbagelata E; Department of Internal Medicine, Lavagna Hospital, Genoa. elenabarbagelata@yahoo.it.
  • Corbi G; Department of Medicine and Health Sciences, University of Molise; Gender Medicine and Aging (GEMEA) Group of the Italian Society of Gerontology and Geriatrics (SIGG). graziamaria.corbi@unimol.it.
  • Ciarambino T; Department of Internal Medicine, Marcianise Hospital, ASL Caserta. tiziana.ciarambino@gmail.com.
  • Politi C; Head of Gender Medicine Area F.A.D.O.I. (Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti), Isernia. cecilia.politi@asrem.org.
  • Moretti AM; President of GISeG, Italian Group for Health and Gender, Bari. moretti.am@libero.it.
Monaldi Arch Chest Dis ; 90(4)2020 Dec 03.
Artigo em Inglês | MEDLINE | ID: mdl-33305554
ABSTRACT
Coronavirus Disease-2019 (COVID-19) is the worst worldwide pandemic with more than 12,000,000 cases and 560,000 deaths until 14th July 2020. Men were more infected by COVID-19 than women, and male subjects with underlying conditions, including diabetes, hypertension, and cardiovascular diseases developed a severe form of the affection, with increased mortality rate. Many factors can contribute to the disparity in disease outcomes, such as hormone-specific reaction and activity of X-linked genes, which modulate the innate and adaptive immune response to virus infection. Until now, only the Remdesivir was approved by FDA (Food Drug Administration) for COVID-19 treatment, although several clinical trials are ongoing worldwide also on other drugs. In this review, we analyzed published studies on several drugs (chloroquine or hydroxychloroquine, remdesivir, favipiravir, lopinavir-ritonavir in combination, tocilizumab, plasma, and immunoglobulins) with some efficacy to COVID-19 in humans, and evaluated if there were a gender analysis of the available data. In our opinion, it is essential to report data about COVID-19 disaggregated by sex, age, and race, because the knowledge of gender differences is fundamental to identify effective and customized treatments to reduce hospitalizations, admissions to intensive care units, and mortality.
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Ensaio clínico controlado / Determinantes_sociais_saude / Estudo prognóstico Aspecto: Determinantes_sociais_saude Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Ensaio clínico controlado / Determinantes_sociais_saude / Estudo prognóstico Aspecto: Determinantes_sociais_saude Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Artigo